Provided by Tiger Trade Technology Pte. Ltd.

Actuate Therapeutics Inc

7.52
+0.10001.35%
Post-market: 7.520.00000.00%16:10 EST
Volume:104.66K
Turnover:783.87K
Market Cap:174.79M
PE:-6.24
High:7.64
Open:7.46
Low:7.30
Close:7.42
52wk High:11.99
52wk Low:5.47
Shares:23.24M
Float Shares:9.28M
Volume Ratio:1.03
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2044
EPS(LYR):-3.2588
ROE:-296.04%
ROA:-95.25%
PB:15.98
PE(LYR):-2.31

Loading ...

Actuate Therapeutics Signs $100M Sales Agreement

TIPRANKS
·
Nov 29

BRIEF-Actuate Therapeutics Inc - Enters At The Market Issuance Sales Agreement With B. Riley And Craig-Hallum - SEC Filing

Reuters
·
Nov 29

Actuate Therapeutics Inc - Enters at the Market Issuance Sales Agreement With B. Riley and Craig-Hallum - SEC Filing

THOMSON REUTERS
·
Nov 29

Actuate Therapeutics Inc - May Sell Common Stock up to $100 Mln - SEC Filing

THOMSON REUTERS
·
Nov 29

Actuate Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
Nov 19

Craig-Hallum Reaffirms Their Buy Rating on Actuate Therapeutics, Inc. (ACTU)

TIPRANKS
·
Nov 14

Actuate Therapeutics Q3 EPS $(0.25) Beats $(0.28) Estimate

Benzinga
·
Nov 14

Actuate Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 23

Actuate Therapeutics - Data to Support FDA and Ema Submissions Beginning Later This Year, Continuing Into Early 2026

THOMSON REUTERS
·
Sep 22

Actuate Therapeutics Inc - Recent Financing Extends Runway Through Key Regulatory Points

THOMSON REUTERS
·
Sep 22

Actuate Therapeutics Inc: Amended Elraglusib Ind Application With Updated Clinical Data From Phase 2 Trial for Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Sep 22

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

GlobeNewswire
·
Sep 22

Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option

GlobeNewswire
·
Sep 12

Actuate Therapeutics Shares Drop After Public Offering Prices

Dow Jones
·
Sep 10

BRIEF-Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

Reuters
·
Sep 10

Actuate Therapeutics Plans Public Offering of Common Shares

MT Newswires Live
·
Sep 10

Actuate Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire
·
Sep 10

BRIEF-Actuate Therapeutics Inc Files For Mixed Shelf Offering Of Up To $250 Million- SEC Filing

Reuters
·
Sep 03

Actuate Therapeutics Inc Files for Mixed Shelf Offering of up to $250 Mln- SEC Filing

THOMSON REUTERS
·
Sep 03

B. Riley Initiates Actuate Therapeutics With Buy Rating, $20 Price Target

MT Newswires Live
·
Aug 26